[go: up one dir, main page]

AR111469A1 - Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma - Google Patents

Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma

Info

Publication number
AR111469A1
AR111469A1 ARP180100945A ARP180100945A AR111469A1 AR 111469 A1 AR111469 A1 AR 111469A1 AR P180100945 A ARP180100945 A AR P180100945A AR P180100945 A ARP180100945 A AR P180100945A AR 111469 A1 AR111469 A1 AR 111469A1
Authority
AR
Argentina
Prior art keywords
same
aminopiridine
prepare
come out
crystal form
Prior art date
Application number
ARP180100945A
Other languages
English (en)
Inventor
Dong Kyun Kim
Su Min Park
Jeong Ki Kang
Hyun Ju
Woo Seob Shin
Young Sung Lee
Kyeong Bae Kim
Seong Ran Lee
Soo Yong Chung
Tae Dong Han
Se Oh
- Kim Jong Gyun Woong
Sang Ho Oh
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63857137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR111469(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of AR111469A1 publication Critical patent/AR111469A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Reivindicación 1: Sal mesilato de N-(5-(4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-ilamino)-4-metoxi-2-morfolinofenil)acrilamida, representada por la fórmula (1). Reivindicación 2: La sal mesilato de la reivindicación 1, que está en una forma cristalina.
ARP180100945A 2017-04-21 2018-04-13 Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma AR111469A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170051687 2017-04-21

Publications (1)

Publication Number Publication Date
AR111469A1 true AR111469A1 (es) 2019-07-17

Family

ID=63857137

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100945A AR111469A1 (es) 2017-04-21 2018-04-13 Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma

Country Status (23)

Country Link
US (3) US11453656B2 (es)
EP (1) EP3612529A4 (es)
JP (2) JP7126514B2 (es)
KR (3) KR102629654B1 (es)
CN (1) CN110869367B (es)
AR (1) AR111469A1 (es)
AU (2) AU2018256227B2 (es)
BR (1) BR112019021868A2 (es)
CA (1) CA3059543A1 (es)
CO (1) CO2019011578A2 (es)
EA (1) EA201992501A1 (es)
IL (2) IL294666B2 (es)
MA (1) MA49696A (es)
MX (2) MX392634B (es)
MY (1) MY201919A (es)
NZ (1) NZ758443A (es)
PH (1) PH12019502370A1 (es)
SA (1) SA519410342B1 (es)
SG (1) SG11201909615YA (es)
TW (1) TWI776882B (es)
UA (1) UA124364C2 (es)
WO (1) WO2018194356A1 (es)
ZA (1) ZA201907687B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
SI3658552T1 (sl) 2017-07-28 2023-11-30 Yuhan Corporation Postopek za pripravo N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il )amino)-4-metoksi-2-morfolinofenil)akrilamida z reagiranjem ustreznega amina s 3-halo-propionil kloridom
KR20200043618A (ko) * 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
EP3885346A4 (en) * 2018-12-21 2022-01-12 Shenzhen TargetRx, Inc. Aminopyrimidine compound used for inhibiting activity of protein kinase
PH12021552030A1 (en) 2019-02-26 2022-08-15 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
CA3140360A1 (en) * 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CN117425651A (zh) * 2021-06-01 2024-01-19 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004309217B2 (en) 2003-12-25 2008-11-06 Eisai R&D Management Co., Ltd Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these
EP1720853B2 (en) 2004-02-11 2023-06-28 Natco Pharma Limited Pharmaceutical compositions of the 2 crystalline form of imatinib mesylate for use in the treatment of chronic myelogenous leukemia
RU2536584C2 (ru) * 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Гетероарильные соединения и их применение
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
US8629132B2 (en) 2009-11-13 2014-01-14 Genosco Kinase inhibitors
EP2649060B1 (en) * 2010-12-06 2017-04-05 MSN Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
EP2736895B1 (en) 2011-07-27 2016-01-06 Astrazeneca AB 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
CN104540822B (zh) 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
SI3604294T1 (sl) * 2014-10-13 2021-08-31 Yuhan Corporation Spojine in sestavki za moduliranje aktivnosti kinaze mutanta EGFR
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
KR101794186B1 (ko) 2015-10-30 2017-11-08 한국기술교육대학교 산학협력단 전기자동차용 급전장치
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Also Published As

Publication number Publication date
CA3059543A1 (en) 2018-10-25
IL294666B1 (en) 2024-01-01
US12428401B2 (en) 2025-09-30
US11981659B2 (en) 2024-05-14
KR102835717B1 (ko) 2025-07-18
EA201992501A1 (ru) 2020-02-18
US20240279203A1 (en) 2024-08-22
SG11201909615YA (en) 2019-11-28
MX2022006357A (es) 2022-06-23
KR102629654B1 (ko) 2024-01-29
BR112019021868A2 (pt) 2020-05-26
NZ758443A (en) 2023-03-31
US20230021395A1 (en) 2023-01-26
UA124364C2 (uk) 2021-09-01
EP3612529A4 (en) 2020-11-18
SA519410342B1 (ar) 2023-02-09
AU2022203486B2 (en) 2024-06-06
EP3612529A1 (en) 2020-02-26
JP2020517611A (ja) 2020-06-18
US20210139461A1 (en) 2021-05-13
AU2018256227B2 (en) 2022-03-03
IL270018A (es) 2019-12-31
JP2022166179A (ja) 2022-11-01
ZA201907687B (en) 2023-04-26
TW201841910A (zh) 2018-12-01
IL294666A (en) 2022-09-01
MX392634B (es) 2025-03-24
MA49696A (fr) 2020-06-03
JP7126514B2 (ja) 2022-08-26
CO2019011578A2 (es) 2020-02-28
AU2022203486A1 (en) 2022-06-09
AU2018256227A1 (en) 2019-10-31
PH12019502370A1 (en) 2020-07-13
TWI776882B (zh) 2022-09-11
CN110869367B (zh) 2023-09-15
KR20180118535A (ko) 2018-10-31
KR20250111074A (ko) 2025-07-22
IL270018B (en) 2022-08-01
CN110869367A (zh) 2020-03-06
JP7390444B2 (ja) 2023-12-01
WO2018194356A1 (en) 2018-10-25
MY201919A (en) 2024-03-23
KR20230175161A (ko) 2023-12-29
US11453656B2 (en) 2022-09-27
IL294666B2 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
AR111469A1 (es) Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
MX391812B (es) Agonista fxr derivado de esteroides.
MX2017002670A (es) Inhibidores de glucosidasa.
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2018010191A (es) Inhibidores de glucosidasa.
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
AR103680A1 (es) Inhibidores selectivos de bace1
EA201692356A1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
EA201790112A1 (ru) Гетероциклические соединения и их применение в качестве ингибиторов орфанного рецептора гамма-t, родственного рецепторам ретиноидов (ror)
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
CO2021000932A2 (es) Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
EA201591684A1 (ru) Кристаллические формы ингибиторов тирозинкиназы и их солей
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы